Watch Ticker

Immuneering Corporation Class A Common Stock

Go to Immuneering Corporation Class A Common Stock Website

$3.56

0.13 (3.79%)

Live

Previous Close

$3.43

Day Range

$3.37 - $3.58

Previous Day Range

$3.25 - $3.45

Market Cap

$121.3 million USD

Day Vol.

228349

Previous Day Vol.

266991

Currency

USD

Primary Exchange

Nasdaq

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug dev...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Immuneering Corporation - Immuneering Reports Positive Overall Survival Data for Atebimetinib (IMM-1-104) from Ongoing Phase 2a Trial in First-Line Pancreatic Cancer Patients

Immuneering reported positive data from its ongoing Phase 2a trial of atebimetinib (IMM-1-104) in combination with modified Gemcitabine/nab-Paclitaxel (mGnP) for first-line pancreatic cancer patients, including 94% overall survival at 6 months and a favorable tolerability profile.

Related tickers: IMRX.

Read Full Article

N/A - Immuneering to Provide Updates from Phase 2a Clinical Trial of IMM-1-104 in First-Line Pancreatic Cancer Patients on Tuesday, June 17, 2025

Immuneering Corporation announced that it will host a conference call to provide updates from its ongoing Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.

Related tickers: IMRX.

Read Full Article

Trending Tickers

Please sign in to view